References
- Gupta M., Noel G. J., Schaefer M., Friedman D., Bussel J., Johann‐Liang R. Cytokine modulation with immune gamma‐globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J Clin Immunol 2001; 21: 193–9
- Chien Y. H., Chang K. W., Yang Y. H., Lu M. Y., Lin Y. T., Chiang B. L. Association between levels of TNF‐alpha and TNF‐alpha promoter −308 A/A polymorphism in children with Kawasaki disease. J Formos Med Assoc 2003; 102: 147–50
- Nishimura S., Zaitsu M., Hara M., Yokota G., Watanabe M., Ueda Y., et al. A polymorphism in the promoter of the CD14 gene (CD14/−159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr 2003; 143: 357–62
- Dinarello C. A. The role of the interleukin‐1‐receptor antagonist in blocking inflammation mediated by interleukin‐1. N Engl J Med 2000; 343: 732–4
- Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF‐mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798–802
- Rosenfeld E. A., Corydon K. E., Shulman S. T. Kawasaki disease in infants less than one year of age. J Pediatr 1995; 126: 524–9
- Brenner J. L., Jadavji T., Pinto A., Trevenen C., Patton D. Severe Kawasaki disease in infants: two fatal cases. Can J Cardiol 2000; 16: 1017–23
- Newburger J. W., Takahashi M., Gerber M. A., Gewitz M. H., Tani L. Y., Burns J. C., et al. Diagnosis, treatment, and long‐term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708–33
- Weiss J. E., Eberhard B. A., Chowdhury D., Gottlieb B. S. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808–10
- Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W. L., et al. Effectiveness of TNF‐alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 1303–7
- Tan A. L., Holdsworth J., Pease C., Emery P., McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003; 62: 373–4
- Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 2004; 6: 137–46
- Brown S. L., Greene M. H., Gershon S. K., Edwards E. T., Braun M. M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty‐six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–8
- Mohan N., Edwards E. T., Cupps T. R., Oliverio P. J., Sandberg G., Crayton H., et al. Demyelination occurring during anti‐tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–9
- Roberts L., McColl G. J. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 2004; 34: 687–93
- Armbrust W., Kamphuis S. S., Wolfs T. W., Fiselier T. J., Nikkels P. G., Kuis W., et al. Tuberculosis in a nine‐year‐old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2004; 43: 527–9
- Dhillon R., Clarkson P., Donald A. E., Powe A. J., Nash M., Novelli V., et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94: 2103–6